RARE vs SABR · rev $350.0M vs rev $1.47B
Ultragenyx (RARE) versus Sabre Corpo (SABR) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Sabre Corpo (SABR) is a software - infrastructure company listed on NASDAQ.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported SABR revenue for 2026-06-30 was $1.47B. Net income was -$28.1M. Revenue was up 93.6% from 2026-03-31 to 2026-06-30. SABR currently screens at market cap $735.3M.
RARE currently screens at market cap $2.79B. SABR currently screens at market cap $735.3M.
Not investment advice. Open the RARE and SABR stock pages for the full models.
Not investment advice.